Bosutinib

Bosutinib is an oral tyrosine kinase inhibitor, specifically targeting the Bcr-Abl and Src family kinases. It is a prescription medication used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults who have not responded well to or cannot tolerate other treatments.
Bosutinib works by inhibiting the activity of the Bcr-Abl protein, which is responsible for the uncontrolled cell growth in CML and Ph+ ALL. By blocking the action of this protein, bosutinib helps to slow down the progression of these blood cancers and improve overall patient outcomes.
Bosutinib is typically prescribed for patients who have developed resistance to other therapies or have experienced intolerable side effects from other treatments. The medication is taken once daily with a meal, and its effectiveness may be enhanced when used in combination with other targeted therapies.
As with any cancer treatment, it is important for patients to discuss the potential benefits and risks of bosutinib with their healthcare provider. Regular monitoring of blood counts and liver function is necessary to ensure patient safety and optimize treatment results.